Advertisement

Parallel trade of pharmaceutical drugs in Denmark

Abstract

In Denmark, wholesalers started selling parallel traded drugs to hospitals in 1992, responding to demand for lower priced products. After the government had implemented a series of health policy reforms, including a law that required pharmacists to dispense parallel traded products, the respective sales and market shares picked up markedly. By the third quarter of the 1990s, parallel import penetration had grown to approximately 10% where it stabilized despite a significant, government induced, reduction of average prices on locally sourced brands starting in 1999.

Keywords

Price Change Average Price Pharmaceutical Drug Price Behaviour Generic Competition 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 26.
    Vallgårda S. et al. (2001), Healthcare Systems in Transition: DenmarkGoogle Scholar
  2. 27.
    Vallgårda S. et al. (2001), Healthcare Systems in Transition: Denmark, Vol. 8, Nr. 7Google Scholar
  3. 28.
    Vallgårda S. et al. (2001), Healthcare Systems in Transition: Denmark, Vol. 8, Nr. 7Google Scholar
  4. 29.
    Vallgårda S. et al. (2001), Healthcare Systems in Transition: Denmark, Vol. 8, Nr. 7, Page 30Google Scholar
  5. 30.
    EFPIA (2006), The Pharmaceutical Industry in Figures, Page 37, BrusselsGoogle Scholar
  6. 31.
    Bouvy F. (2003) Overview of pricing and reimbursement measures taken since January 1993, Working Document, EFPIA, BrusselsGoogle Scholar
  7. 32.
    Interview with Jørgen Clausen, Copenhagen, June 4th, 2004Google Scholar
  8. 34.
    Bouvy F (2003) Overview of pricing and reimbursement measures taken since January 1993, Working Document, EFPIA, BrusselsGoogle Scholar
  9. 35.
    Treaty establishing the European Community, Official Journal C 325 of 24 December 2002, European UnionGoogle Scholar
  10. 36.
    Interview with Bøgh-Sørensen et al., Orifarm A/S, Odense, 06.06.2004Google Scholar
  11. 37.
    Interview with Bøgh-Sørensen et al. Orifarm A/S, 06.05.2004, Odense, DenmarkGoogle Scholar
  12. 38.
    Interview with Bøgh-Sørensen H. et al., Orifarm A/S, 06.05.2004, Odense, DenmarkGoogle Scholar
  13. 39.
    Bouvy F. (2003) Overview of pricing and reimbursement measures taken since January 1993, Working Document, EFPIA, BrusselsGoogle Scholar
  14. 40.
    Bouvy F (2003) Overview of pricing and reimbursement measures taken since January 1993, Working Document, EFPIA, BrusselsGoogle Scholar
  15. 41.
    Interview with H. Bøgh-Sørensen et al., Orifarm A/S, Odense, 06.06.2004Google Scholar
  16. 42.
    Interviewwith H. Bøgh-Sørensen et al., Orifarm A/S, Odense, 06.06.2004Google Scholar
  17. 43.
    Interview with J. Clausen, June, 2004Google Scholar
  18. 44.
    EFPIA (2006), The Pharmaceutical Industry in Figures, Page 16, BrusselsGoogle Scholar
  19. 45.
    LMI (2006), Facts and Figures 2006: Medicines and Healthcare, P. 88Google Scholar
  20. 46.
    ECJ Court Judgement 15/74, Centrafarm et al. vs. Stanley Drug Inc., European Court of Justice, 1974Google Scholar
  21. 47.
    Vallgårda S. et al. (2001), Healthcare Systems in Transition: Denmark, Vol. 8, Nr. 7, Page 67Google Scholar
  22. 48.
    Interview with H. Bøgh-Sørensen et al., Orifarm A/S, Odense, 06.06.2004Google Scholar
  23. 50.
    Interview with H. Bøgh-Sørensen et al., Orifarm A/S, Odense, 06.06.2004Google Scholar
  24. 57.
    West P. et al (2003) Benefits to Payers and Patients From Parallel Trade (2002), The York Health Economics ConsortiumGoogle Scholar
  25. 58.
    Haigh, J. (2003) Parallel Trade in Europe — Assessing the Reality of Payer and Patient Savings: A Review of the York Health Economics Consortium Report, IMS-Consulting, London, http://www.imshealth.com/ims/portal/front/articleC/0,2777,6599_41382706_43286344,00.html, accessed on 18.02.2006Google Scholar
  26. 59.
    West P. et al (2003) Benefits to Payers and Patients From Parallel Trade (2002), The York Health Economics ConsortiumGoogle Scholar
  27. 60.
    Kanavos P. and Costa-Font J (2005), Pharmaceutical parallel trade in Europe: stakeholder and competition effects, Economic Policy October 2005, Page 778Google Scholar
  28. 64.
    Overview of pricing and reimbursement reforms taken by European countries since 1993, EFPIA, 2003Google Scholar
  29. 65.
    Frank R. and Salkever D. (1997), Generic Entry and Pricing of Pharmaceuticals, J. of Econ. &Mgt. Strategy, 1997, Issue 1, Page 75–90Google Scholar
  30. 67.
    Reiffen D. and Ward M. (2002), Generic Drug Industry Dynamics, The Federal Trade CommissionGoogle Scholar
  31. 68.
    Reiffen D. and Ward M. (2002), Generic Drug Industry Dynamics, The Federal Trade CommissionGoogle Scholar
  32. 69.
    EFPIA (2006), The Pharmaceutical Industry in Figures 2006 EditionGoogle Scholar
  33. 71.
    Pedersen M. (2006), The economic impact of parallel import of pharmaceuticalsGoogle Scholar
  34. 72.
    DLI — Dansk Lægemiddel Information Sales Database, 2004Google Scholar
  35. 73.
    M. Ganslandt, K.E. Maskus (2004), J. of Health Economics 23 (2004) 1035–1057, p. 1049CrossRefGoogle Scholar
  36. 74.
    Kanavos P. and Costa-Font J (2005), Pharmaceutical parallel trade in Europe: stakeholder and competition effects, Economic Policy October 2005, p 778Google Scholar
  37. 75.
    West P. et al. (2002) Benefits to Payers and Patients From Parallel Trade, The York Health Economics ConsortiumGoogle Scholar
  38. 76.
    Pedersen K. et al. (2006), The Economic Impact of parallel import of pharmaceuticals, University of Southern DenmarkGoogle Scholar
  39. 77.
    IMS Health (2006), Pricing and market access review 2006, Page 22Google Scholar
  40. 79.
    IMS Health (2006), Pricing and Market Access Review 2006Google Scholar

Copyright information

© Birkhäuser Verlag AG 2008

Personalised recommendations